Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

Cited by (525)

Items 301–400 of 525

1. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting
   Thozhukat Sathyapalan, Stephen Lawrence Atkin, Eric S. Kilpatrick · 2008 · Diabetic Medicine
2. Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review
   Michel de Lorgeril, Tomohito Hamazaki, Willy Kostucki, Harumi Okuyama, Bruno Pavy, Anne‐Thea McGill, Mikael Rabaeus · 2012 · Reviews on Recent Clinical Trials
3. How can we prevent cardiovascular disease in diabetes
   Olov Wiklund, Liliana Håversen, Camilla Pettersson, Lillemor Mattsson Hultén · 2007 · Journal of Internal Medicine
4. Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient
   Gerald Francis Watts, Fredrik Karpe · 2011 · Postgraduate Medical Journal
5. Reassessment of cardiovascular risk in diabetes
   Jonathan R. Jaffe, Soma S. Nag, Pamela B. Landsman, Charles M. Alexander · 2006 · Current Opinion in Lipidology
6. Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review
   Timothy E. Raymond, Russell E. Raymond, Abraham Michael Lincoff · 2013 · Future Cardiology
7. Coronary Artery Disease
   Tamio Teramoto, Junichi Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida et al. · 2013 · Journal of Atherosclerosis and Thrombosis
8. Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies
   Pamela B. DeGuzman, Kwame Osei Akosah, Allan G. Simpson, Kirk E Barbieri, Gregory C Megginson, Randal I. Goldberg, George Beller · 2012 · Diabetes and Vascular Disease Research
9. Diabetic dyslipidemia and the metabolic syndrome
   William T. Cefalu · 2008 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
10. Linking diabetes and atherosclerosis
    Riccardo Candido, Stella Bernardi, Terri J. Allen · 2009 · Expert Review of Endocrinology & Metabolism
11. Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category
    Adam B. Polis, Nicola I. Abate, Alberico Luigi Catapano, Christie Mitchell Ballantyne, Michael H. Davidson, Steven S. Smugar, Andrew M. Tershakovec · 2009 · Metabolic Syndrome and Related Disorders
12. Cardiovascular Manifestations of Insulin Resistance
    Veer Chahwala, Rohit Romesh Arora · 2009 · American Journal of Therapeutics
13. Residual Vascular Risk in T2DM: The Next Frontier
    Michel P., Attucci Sylvie, Michel F. · 2011 · InTech eBooks
14. Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis
    René Rodríguez‐Gutiérrez, Mariana García-Leal, Karina Raygoza-Cortez, Andrea Flores-Rodríguez, Marcela Moreno-Alvarado, E. Maximiliano Heredia-Martínez, Briana Vazquez-Baquerizo, Raul Guerra-Espiricueta, Valeria Muñoz-Silva, José Gerardo González‐González · 2023 · Endocrine
15. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes
    Po-Hsun Chen, Jun‐Sing Wang, Shih-Yi Lin, Cheng-Hung Li, Chi-Yen Wang, Ching-Yun Hu, Chia‐Po Fu, Yi-Ting Tsai, Ang-Tse Lee, Yu‐Wei Chen et al. · 2018 · Current Medical Research and Opinion
16. Dyslipidemia in Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
17. More Clinical Lessons from the FIELD Study
    Sergio Fazio · 2009 · Cardiovascular Drugs and Therapy
18. Atorvastatin Decreases Stearoyl‐CoA Desaturase Gene Expression in THP‐1 Macrophages Incubated with Oxidized LDL
    Paula Martín‐Fuentes, A.L. García-Otín, Luisa Calvo, Diego Gómez‐Coronado, Fernando Civeira, Ana Cenarro · 2008 · Lipids
19. Reducing morbidity and mortality in high risk patients with statins
    PRAKASH C. DEEDWANIA, Vibhuti N. Singh · 2009 · Vascular Health and Risk Management
20. Lower might be better – It matters how you get there, and in whom
    Jennifer G. Robinson · 2016 · European Heart Journal
21. Study of the metabolic effects of Ramadan fasting on patients with type 2 diabetes. Relation to glycemic control, hypoglycemic events and diabetic complications
    Azza Ismail, Magdy Helmy Zikry Megallaa, Mai Badrah, Menna Farghaly · 2021 · Clinical Diabetology
22. Assessing cardiovascular risk factors and selecting agents to successfully treat patients with type 2 diabetes mellitus.
    Mark D. Baldwin · 2011 · PubMed
23. Pharmacogenetics of the PPAR Genes and Cardiovascular Disease
    Sharon Cresci · 2007 · Pharmacogenomics
24. Targeting LDL Dyslipidemia for Controlling Progression of Nephropathy in Diabetic Population: A Cross Sectional Analytical Study
    Kamran Mahmood Ahmed Aziz · 2013 · DOAJ (DOAJ: Directory of Open Access Journals)
25. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
    Peter Paul Toth · 2016 · The American Journal of Cardiology
26. Patients’ Understanding of the Relationship Between Their Diabetes and Periodontal Disease
    Oluwamurewa Oguntimein, James Thomas Butler, Sharon M. Desmond, Kerry M. Green, Xin He, Alice M. Horowitz · 2020 · The Journal of the American Board of Family Medicine
27. Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2
    Antonio Ruiz‐García, Ezequiel Arranz-Martínez, Ignacio Morón Merchante, Vicente Pascual Fuster, Juan José Tamarit, Ferran Trias, Xavier Pintó, Juan Francisco Ascaso · 2018 · Clínica e Investigación en Arteriosclerosis
28. The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of “real world” practice in people with diabetes
    Manju Bengaluru Jayanna, Jennifer G. Robinson · 2019 · Diabetes Obesity and Metabolism
29. Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes – a nation-wide study from Finland in 1996–2012
    Klas Winell, Arto Pietilä, Veikko V Salomaa · 2019 · Annals of Medicine
30. Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study
    Junwei Wang, Jiang-Feng Ke, Zhi-Hui Zhang, Junxi Lu, Lianxi Li · 2022 · Diabetology & Metabolic Syndrome
31. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein
    Paul J.W.H. Kappelle, L. Zwang, Menno Volkert Huisman, Jan Dirk Banga, Wim J. Sluiter, Geesje M. Dallinga‐Thie, Robin P. F. Dullaart · 2009 · Expert Opinion on Therapeutic Targets
32. Management of coronary artery disease in patients with type 2 diabetes mellitus
    Sundararajan Srikanth, PRAKASH C. DEEDWANIA · 2007 · Current Cardiology Reports
33. Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
    Joaquim Barreto, Beatriz Luchiari, Vaneza Lira Waldow Wolf, Isabella Bonilha, Ticiane Gonçalez Bovi, Barbara Assato, Ikaro Soares Santos Breder, Sheila T. Kimura-Medorima, Daniel Munhoz, Thiago Quinaglia et al. · 2022 · Diagnostics
34. Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review
    Nikolaos Velidakis, Panagiotis Stachteas, Evangelia Gkougkoudi, Christodoulos E. Papadopoulos, Nikolaos P. E. Kadoglou · 2024 · Pharmaceuticals
35. Riesgo elevado de disfunción lipoproteica en la diabetes mellitus tipo 2
    Rafael Carmena · 2008 · Revista Española de Cardiología Suplementos
36. Low density lipoprotein‐cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
    Thozhukat Sathyapalan, Stephen Lawrence Atkin, Eric S. Kilpatrick · 2009 · Diabetes Obesity and Metabolism
37. Control of Lipids at Baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
    Pambianco, Georgia, Lombardero, Manuel, Bittner, Vera, Forker, Alan, Kennedy, Frank, Krishnaswami, Ashok, Mooradian, Arshag D., Pop‐Busui, Rodica, Rana, Jamal S., Rodriguez, Annabelle et al. · 2009 · Preventive Cardiology
38. Clinical Insights From the Treating to New Targets Trial
    David D. Waters · 2009 · Progress in Cardiovascular Diseases
39. Beneficial Effect of Atorvastatin on Renal Function in Patients with Type 2 Diabetes
    Masami Tanaka · 2011 · Journal of International Medical Research
40. Patterns of type 2 diabetes monitoring in rural towns: How does frequency of HbA1c and lipid testing compare with existing guidelines?
    Christine Louise Paul, Leon Piterman, Jonathan E. Shaw, Catherine N Kirby, Daniel Barker, Jennifer Robinson, Kristy Fakes, Ken A. Sikaris, Alessandra Bisquera, Rob Sanson‐Fisher · 2016 · Australian Journal of Rural Health
41. Hypertriglyceridaemia predicts subsequent long‐term risk of cardiovascular events in Chinese adults: 23‐year follow‐up of the Daqing Diabetes Study
    Jinping Wang, Xiaoxia Shen, Siyao He, Yali An, Qiuhong Gong, Hui Li, Bo Zhang, Ying Shuai, Yanyan Chen, Yinghua Hu et al. · 2019 · Diabetes/Metabolism Research and Reviews
42. Does the metabolic syndrome help to select patients requiring high statin dose?
    André Jacques Scheen · 2006 · The Lancet
43. Significance of LDL-C lowering therapy in diabetic patients
    Mary Sergio Martinez-Hervas, Mark Rafael Carmena, Mary Juan F Ascaso · 2011 · Clinical Lipidology
44. Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials
    Ivan Tkáč · 2007 · Diabetes Research and Clinical Practice
45. Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes
    Eberhard Standl · 2012 · Diabetes and Vascular Disease Research
46. Time to onset of type 2 diabetes mellitus in Ghana
    Michael Asamoah-Boaheng, Eric Yeboah Tenkorang, Osei Sarfo‐Kantanka · 2018 · International Health
47. Paradoxical Negative HDL Cholesterol Response to Atorvastatin and Simvastatin Treatment in Chinese Type 2 Diabetic Patients
    Yu‐Hung Chang, Kun-Cheng Lin, Dao‐Ming Chang, Chang‐Hsun Hsieh, Lee Yau-Jiunn · 2013 · The Review of Diabetic Studies
48. What the Guidelines Do Not Say: Statin Non-benefit Groups
    Pamela Bowe Morris, Kellie H. McLain · 2014 · Current Atherosclerosis Reports
49. Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study
    Salgaonkar V. Jaywant, Amit Kumar Singh, Mundkur S. Prabhu, R. Ranjan · 2016 · Indian Heart Journal
50. Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update
    Adrian Liew, Sunita Bavanandan, Chuan‐Ming Hao, Soo Kun Lim, Narayan Prasad, Manisha Sahay, Paweena Susantitaphong, Veena Roberts, Eranga Sanjeewa Wijewickrama, Muh Geot Wong et al. · 2025 · Nephrology
51. Improving Representation of Underserved Populations in Cardiovascular Research
    Irving K. Loh, Tyler E. Miller, Rahul Aggarwal, Teriya M. Richmond · 2025 · Journal of the American Heart Association
52. Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
    L. Kennedy · 2008 · Yearbook of Medicine
53. Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular
    Vivencio Barrios, Carlos Escobar · 2011 · Revista Española de Cardiología Suplementos
54. Combination lipid therapy in type 2 diabetes mellitus
    Bruno L Vergès · 2011 · Expert Opinion on Pharmacotherapy
55. Achievement of the ABC goal among Canadians with type 2 diabetes and the influence of physical activity: data from the Canadian Health Measures Survey
    Alexis Marcotte‐Chénard, René Maréchal, Ahmed Ghachem, Alan Arthur Cohen, Éléonor Riesco · 2023 · Applied Physiology, Nutrition, and Metabolism
56. Diabetes Mellitus and Metabolic Syndrome
    Francesco Cosentino, Lars Rydén, Pietro Francia, Linda Mellbin · 2009
57. Statins and Monitoring of Liver Function Tests
    Karam Kostner, Laurence Guy Howes · 2007 · Drug Safety
58. Early diagnostic of diabetic foot using thermal images
    Luis Alberto Vilcahuaman Cajacuri · 2013
59. Insulin Resistance and Cardiovascular Disease
    Cecilia C. Low Wang · 2009 · Humana Press eBooks
60. A European, Observational, 3‐Year Cohort Comparative Study on the Safety of the Fixed Dose Combination Pravastatin 40 mg/Fenofibrate 160 mg vs. Statin Alone in Real Clinical Practice: The POSE Study
    Nikolaos Papadopoulos, Eleni Arvaniti, Theodoros P. Angelopoulos, Κωνσταντίνος Τζιόμαλος, Manuel Suárez Tembra, José Luis Díaz-Díaz, Sophie De Niet, Stéphanie Da Silva, John Doupis · 2024 · Pharmacoepidemiology and Drug Safety
61. Advances in Lipid Testing and Management in Patients with Diabetes Mellitus
    Madhuri Mukhopadhyay Vasudevan, Christie Mitchell Ballantyne · 2009 · Endocrine Practice
62. Perfil glicometabólico inicial em pacientes com síndrome coronariana aguda e síndrome metabólica
    Carlos M. C. Monteiro, L. M. Oliveira, Maria Cristina de Oliveira Izar, Tatiana Helfenstein, Andreza Oliveira dos Santos, Simone Matheus Fischer, Sahana W. Barros, Luiz Fernando Muniz Pinheiro, Antônio Carlos Carvalho, Francisco Antônio Helfenstein Fonseca · 2009 · Arquivos Brasileiros de Cardiologia
63. Tratamiento integral de la dislipidemia diabética: beneficios y nuevas alternativas terapéuticas
    Rafael Carmena, Juan Francisco Ascaso · 2010 · Medicina Clínica
64. Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data
    Sabita S. Soedamah‐Muthu, Johanna Marianne Geleijnse, Erik J. Giltay, Daan Kromhout · 2012 · BMJ Open
65. Management of Diabetes Mellitus
    Alicia Josephine Jenkins, EMMA S. SCOTT, Jordan Fulcher, Gary Kilov, Andrzej S. Januszewski · 2018 · Contemporary cardiology
66. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Marja‐Riitta Taskinen · 2006 · Nutrition Metabolism and Cardiovascular Diseases
67. Lipid lowering in diabetes mellitus
    D. J. Betteridge · 2008 · Current Opinion in Lipidology
68. Statin tedavisinde hasta uyumu: Medya ne kadar etkili?
    Gökhan Dinçer, Zeynep Sayın Dincer, Aybüke Demir Alsancak, Yakup Alsancak, Enes Gümüş, Oğuz Tekin · 2016 · Turkish Journal of Family Practice
69. Diabetic Dyslipidemia
    Francesco Paneni, Francesco Cosentino · 2015 · Springer eBooks
70. Diabetes-Related Dyslipidemia and Cardiovascular Events
    Vivian Andrew Fonseca, Dragana Lovre · 2017 · The American Journal of the Medical Sciences
71. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids
    Hani Mohamed Sabbour, Deepak L. Bhatt, Yaser Elhenawi, Asma Khaled Aljaberi, Layal Bennani, Tarek M. Fiad, Khwaja Yousuf Hasan, Shahrukh Hashmani, Rabih A. Hijazi, Zafar Khan et al. · 2024 · Cardiovascular Drugs and Therapy
72. Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
    Michel Paul Hermans, Evariste Bouénizabila, Daniel Amoussou-Guénou, Sylvie A. Ahn, Michel F. Rousseau · 2015 · Cardiovascular Diabetology
73. Statin use and low-density lipoprotein cholesterol target achievement for primary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: a multicenter cross-sectional study in Sri Lanka
    Warsha De Zoysa, Thilak Priyantha Weerarathna, Nuwan Darshana, Keddagoda Gamage Piyumi Wasana, B. Piyasekara, M. M. P. T. Jayasekara, Vathulan Sujanitha, Shehan Silva, Chamila D. Mettananda, G. U. Ramadasa et al. · 2025 · PLoS ONE
74. Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS
    Philip R. Liebson · 2008 · Preventive Cardiology
75. Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients
    Sandra J. Hamilton, Gerard T. Chew, Timothy M. E. Davis, Gerald Francis Watts · 2011 · Metabolism
76. Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?
    Yehuda Handelsman, Vivian Andrew Fonseca, Julio Rosenstock · 2011 · Expert Review of Clinical Pharmacology
77. Infradiagnóstico de complicaciones crónicas de la diabetes mellitus: utilidad de una revisión sistemática en una sola visita
    Mercè Fernández-Miró, Cristina Colom, Ariadna Lloveras, Gemma Llauradó, Juan José Chillarón · 2012 · Endocrinología y Nutrición
78. Temporal decline in non–high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease
    Gloria Lena Vega, Jijia Wang, Scott M. Grundy · 2020 · Journal of clinical lipidology
79. A Pediatric Opportunity in Adolescents to Prevent Adult Heart Attacks
    David S. Schade, Shirley J. Murphy, Vernat J. Exil, R. Philip Eaton · 2018 · World Journal of Cardiovascular Diseases
80. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
81. Diabetic dyslipidemia: a practical guide to therapy.
    John M. Tovar, Oralia V. Bazaldua, Alexandra Loffredo · 2008 · PubMed
82. Treatment and associated outcomes of type 2 diabetes mellitus patients with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis
    Jens Aberle, Daniel Duerschmied, Martin Grond, Michael Lehrke, Stéphan Martin, Sven‐Oliver Tröbs, Michael Schultze, Nils Kossack, Lena Margareta Richter, Maximilian Gabler · 2025 · Cardiovascular Diabetology
83. Optimizing lipid control in Taiwanese diabetic patients: A collaborative consensus by the Diabetes Association of the Republic of China (Taiwan) and the Taiwanese Association of Diabetes Educators
    Feng‐Chih Shen, Chih‐Hsun Chu, Jung‐Fu Chen, Chin‐Sung Kuo, Chih‐Yao Hsu, Ching‐Han Lin, Yi‐Jing Sheen, Sheng‐Chiang Su, Kai‐Jen Tien, Chieh‐Hua Lu et al. · 2024 · Journal of Diabetes Investigation
84. Ethnic Difference in Lipid Profiles
    Lei Zhang, Qing Qiao, Yanhu Dong · 2012 · InTech eBooks
85. Novel concepts in lipoprotein particle metabolism and regulation
    Konstantinos N. Aronis, Christos Socrates Mantzoros · 2013 · Metabolism
86. Multiple pharmacological interventions targeting cardiovascular disease risk factors in individuals with type 2 diabetes-systematic review
    Hanan Khalil, Kevin Mc Namara, Yijun Pan · 2013 · journal of Diabetes Research and Clinical Metabolism
87. Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome
    Adi Mehta · 2010 · Postgraduate Medicine
88. Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
    Elisenda Climent, Jesús Millán, Juan Francisco Ascaso, Manuel Suárez Tembra, Carlos Morillas, Fernando Civeira, José María Bellón, Juan Pedro‐Botet, the Spanish Atherosclerosis Society Working Group on Atherogenic Dyslipidaemia · 2023 · Lipids
89. Association of Renal Function and Statin Therapy with Lipoprotein(a) in Patients with Type 2 Diabetes
    Chika Hiraishi, Sadako Matsui, Takai Kojima, Ryo Sato, Kiyotaka Ando, Kei Fujimoto, Hiroshi Yoshida · 2023 · Journal of Atherosclerosis and Thrombosis
90. Risk Factors for Premature Death in Diabetes Patients who Undergo Amputations below Ankle Level
    Therese Wilbek Fabricius, Rasmus Bo Jansen, Bo Jørgensen, Ole Lander Svendsen · 2017 · Experimental and Clinical Endocrinology & Diabetes
91. Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus
    MengHee Tan, Mark MacEachern · 2020 · Clinics in Geriatric Medicine
92. Frequency Monitoring of Hemoglobin A1c, Low-Density Lipoprotein, and Urine Protein Laboratory Testing: A College of American Pathologists Q-Probes Study
    Peter L. Perrotta, Ryan Jones, Rhona J. Souers, Teresa P. Darcy, Peter J. Howanitz · 2014 · Archives of Pathology & Laboratory Medicine
93. Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease
    Antonio Pérez, Cintia González, Miguel Ángel Hernández-Presa, Jakson Roberto Gaeski de Chaves · 2011 · Endocrinología y Nutrición (English Edition)
94. Estrategia de tratamiento de la dislipemia y consecución de objetivos en la población española con diabetes tipo 2 sin enfermedad cardiovascular
    Antonio Pérez, Cintia González, Miguel Ángel Hernández-Presa, Jakson Roberto Gaeski de Chaves · 2011 · Endocrinología y Nutrición
95. Rehabilitation (EACPR) Developed with the special contribution of the European Association for Cardiovascular Prevention & Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) : The Fifth
    Christiaan J. Vrints, David Wood, José Luis Zamorano, Faiez M. Zannad, Şehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Shah B J Ebrahim, Giuseppe Germanò, Richard F. Hobbs et al. · 2013
96. Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
    L. Kennedy · 2008 · Yearbook of Endocrinology
97. Novel bisphosphonates as inhibitors of isoprenoid biosynthesis
    Brian M. Wasko · 2011
98. Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.
    Eydoxia K. Mitsiou, Κωνσταντίνος Τζιόμαλος, Panagiotis G. Anagnostis, Asterios I. Karagiannis, Vasilios Gabriel Athyros · 2009 · PubMed
99. Increased high-risk plaque burden in type 2 diabetes: a 10-year follow-up study
    Emilie L. Gaillard, Sophie H. M. Cramer, Nordin M.J. Hanssen, Michiel J. Bom, Steven A. J. Chamuleau, R. Nils Planken, Andrew Choi, S. Matthijs Boekholdt, Erik S.G. Stroes, Paul Knaapen et al. · 2025 · Cardiovascular Diabetology
100. Individualized Cardiovascular Risk Assessment
     Eva Szabov · 2012 · InTech eBooks